{
  "docId": "019de075-cd17-7685-9273-fb1c731af40f",
  "docSlug": "16b2d7592f4634ac7cd717a996934f07",
  "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 35,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 14,
  "notes": "The slide includes specific footnotes regarding non-GAAP adjustments and share buyback activity.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/21",
  "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f",
  "deckJsonHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f.json",
  "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.14,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "1. Non-GAAP loss from continuing operations consists of GAAP loss before taxes excluding share-based compensation expense and non-cash interest expense; see reconciliation on Slide 20 and the section titled \"Non-GAAP Financial Measures\" on Slide 2 for more information. 2. Cash, cash equivalents and marketable securities. SBC, Share-Based Compensation.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d9c8889a-4603-4965-bdd5-87174796e6bc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.05,
        "y": 0.225
      },
      "kind": "table",
      "text": "Financial metrics table comparing Q2 2023 and Q2 2022",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "845a8e0e-f5a4-441e-932a-499b47bc1c8a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.05,
        "y": 0.11
      },
      "kind": "title",
      "text": "Significant Capital Returns from a Position of Strength",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1249cdac-b1ee-407d-8af3-66378ec4178e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.45,
        "x": 0.05,
        "y": 0.04
      },
      "kind": "title",
      "text": "Q2 2023 Financial Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f9ba305-2072-4e22-98d1-a458e700c83c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 25,
      "from": 19,
      "beatId": "94e3fc43-5901-462d-839a-07bb0f06e654",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The document outlines the company's financial update and expected milestones",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}